Enanta Pharmaceutica (ENTA) 27.03 $ENTA Forget Valeant,

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Enanta Pharmaceutica (ENTA) 27.03 $ENTA

Forget Valeant, Buy These 5 Drug Stocks Instead
Arpita Dutt - Zacks Investment Research - Thu Mar 17, 9:10AM CDT
It's time to focus on drug stocks with interesting pipelines, good prospects and favorable Zacks Ranks.
SGYP: 2.78 (+0.16), VRX: 31.09 (-2.34), SCMP: 10.20 (+0.06), ARIA: 6.55 (+0.22), ENTA: 27.03 (+0.51), CORT: 4.29 (+0.10)

Enanta Pharmaceuticals to Present at the Barclays Global Healthcare Conference
Business Wire - Thu Mar 10, 7:00AM CST
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat format, or question and answer session with investors, at the Barclays Global Healthcare Conference on March 17, 2016 at 11:15 a.m. ET.
ENTA: 27.03 (+0.51)

Enanta Pharmaceuticals beats 1Q profit forecasts
Automated Insights - Mon Feb 08, 3:14PM CST
WATERTOWN, Mass. (AP) _ Enanta Pharmaceuticals Inc. (ENTA) on Monday reported fiscal first-quarter earnings of $26.2 million.
ENTA: 27.03 (+0.51)

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2015
Business Wire - Mon Feb 08, 3:02PM CST
--Royalty revenue for paritaprevir containing regimens was $17.9 million
ENTA: 27.03 (+0.51)

Enanta Pharmaceuticals to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
Business Wire - Mon Feb 01, 7:00AM CST
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat format, or question and answer session with investors, at the LEERINK Partners 5th Annual Global Healthcare Conference on February 10, 2016 at 9:15 a.m. ET.
ENTA: 27.03 (+0.51)

Enanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal First Quarter Ended December 31, 2015
Business Wire - Thu Jan 28, 7:00AM CST
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2015 after the U.S. markets close on February 8, 2016. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta's research and development pipeline.
ENTA: 27.03 (+0.51)

Enanta Pharmaceuticals Announces New R&D Initiatives in Hepatitis B Virus and Respiratory Syncytial Virus and Plan to Provide Data Updates on Programs in NASH and HCV at the 34th Annual J.P. Morgan Healthcare Conference
Business Wire - Mon Jan 11, 7:00AM CST
--First subject dosed in phase 1 clinical study with cyclophilin inhibitor EDP-494 for hepatitis C virus infection
JPM: 59.48 (-0.46), ENTA: 27.03 (+0.51)

Enanta Pharmaceuticals Announces That AbbVie Has Initiated Enrollment of Six Global Phase 3 Clinical Studies of Its Once-Daily, Pan-Genotypic Hepatitis C Treatment
Business Wire - Mon Jan 11, 6:10AM CST
--New investigational combination evaluates treatment durations of 12 weeks and as short as eight weeks in genotype 1 patients
ENTA: 27.03 (+0.51)

AbbVie Initiates Enrollment of Six Global Phase 3 Clinical Studies for Once-Daily, Pan-Genotypic Hepatitis C Regimen
PR Newswire - Mon Jan 11, 6:00AM CST
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the initiation of six global Phase 3 clinical studies evaluating the safety and efficacy of its all-oral, once-daily, ribavirin-free investigational hepatitis C virus (HCV) regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, in patients with genotypes 1-6 (GT1-6) chronic HCV infection.
ABBV: 56.12 (-0.24), ENTA: 27.03 (+0.51)

Enanta Pharmaceuticals Announces the U.S. FDA Grants Priority Review to AbbVie's Supplemental New Drug Application for VIEKIRA PAK(R) Without Ribavirin in Genotype 1B Chronic Hepatitis C Virus Patients with Compensated Cirrhosis
Business Wire - Thu Jan 07, 8:09AM CST
--TURQUOISE-III study showed 100 percent sustained virologic response at 12 weeks post-treatment (SVR12) in patients with genotype 1b (GT1b) chronic hepatitis C virus and compensated cirrhosis (Child-Pugh A)
ENTA: 27.03 (+0.51)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Coastal Construction Revamps South Florida's Equipment Game

Updated Category News Views 46

Revolutionizing Equipment Acquisition in South Florida Looks like the sun's shining a bit differently on South Florida's contractors. Coastal Construction Equipment, LLC just announced their big debut as a new player on the Cat Compact™ scene, turning the tides for those in the construction industry. With a plan that's as big as a bulldozer, they'll be breaking ground,...

Continue Reading
NHTSA, Ad Council Unveil New Anti-Buzzed Driving PSAs

Updated Category News Views 43

Taking Aim at a Deadly Habit Everyone's got that gut feeling when a day-long meeting runs over or you're stuck in traffic — impatience morphed with slow burn menace. Now picture a whole campaign gunning for that vibe but in the hands of the young folks, those from 21 to 34. That's what we're talking about here, with the Ad Council and NHTSA serving up some fresh public...

Continue Reading
Sokolove Law Wins $28.8M Verdict for Misdiagnosis Case

Updated Category News Views 90

Jury Awards $28.8 Million in Misdiagnosis Case Well, here's a tale that's bound to ruffle some feathers in the medical community—$28.8 million tossed on the table because an emergency room missed a life-threatening aortic aneurysm. For the uninitiated, this isn't just chump change; it's the cost of dropping the ball when the stakes are as high as a human life. A jury in...

Continue Reading
Villas of Distinction Shines: Bags 11th Gold Travvy

Updated Category News Views 125

Claiming Top Spot Repeatedly Another year, another accolade—Villas of Distinction has clutched its 11th Gold Travvy Award for "Best Villa Rental Company – Overall." This accolade ain't no small potatoes, as it's a testament to the company's unwavering excellence recognized by travel advisors worldwide. These folks, who have their fingers on the pulse of the industry,...

Continue Reading
Silver Oak Sells CCS, Setting Stage for Further Growth

Updated Category News Views 99

Wind Point Partners Acquires CCS: A Strategic Shift All right, let's cut to the chase: Silver Oak just offloaded CCS Facility Services to Wind Point Partners. We're talking about a private equity giant making moves in the janitorial sector. If you find this snoozy, think again. This ain't just about swapping keys of a janitorial firm. It's about money moves and strategic...

Continue Reading
GOFO: Transformative Shifts in U.S. Parcel Dynamics

Updated Category News Views 290

Once upon a time, the last-mile delivery game in the U.S. was the backyard brawl of a few heavy hitters—USPS, UPS, and FedEx slugging it out for package supremacy. But fast-forward to today's parcel market, and things are looking more like a chaotic street party with Amazon now leading the dance. The scene's thinning in some corners while swelling in others. Let's pull...

Continue Reading
International Tower Hill's Q3 Results: Gold Updates

Updated Category News Views 22

An Eye on International Tower Hill's Latest Moves You've got International Tower Hill Mines (TSX: ITH, NYSE American: THM) laying their cards on the table for the third quarter. This ain't just any routine check-in—it's a glimpse at their Livengood Gold Project, standing tall on the promise of gold beyond the horizon. A cool $106 million in cash? Not too shabby, folks....

Continue Reading
PCB Technologies Hits Record Q3 Sales: $62M in Orders

Updated Category News Views 304

PCB Technologies' Stellar Q3: More Than Just Numbers PCB Technologies isn't just riding the wave; it's practically surfing on a tsunami with its latest Q3 financial results. A mix of hard-hitting figures showcases not just growth, but a strategic leap that investors should really be paying attention to. It's about time we peel back the layers and understand what these...

Continue Reading
Millrose Properties Faces Class Action Deadline Amid Turmoil

Updated Category News Views 39

Millrose Properties: Legal Storm Brewing If you've got stock in Millrose Properties, Inc. (NYSE:MRP), you might want to listen up. There's a class action lawsuit in the works that could have quite the impact. Investors have until December 8, 2026, to throw their hat in the ring and maybe even lead the charge on this lawsuit. The Allegations Up Close Let's break down what...

Continue Reading
Iconic Brands Falter in New AI-Driven Consumer Landscape

Updated Category News Views 71

Forget Recognition—It's All About Relevance Now Brand hearts are breaking, folks. That classic suite of household names just took a body blow from the Consequential Brand™ Test. Out of 73, a single champ emerged. Why? Because in the age where AI drives recommendations, it turns out recognizability ain't cutting it. This ain't your granddad’s customer loyalty game...

Continue Reading

Top 5 Most Recently Viewed Articles

RPIA Launches the Innovative RP Alternative Credit Fund

Updated Category News Views 265

Introducing the RP Alternative Credit Opportunities Fund RPIA, a prominent player in the liquid alternatives sector, has just launched the RP Alternative Credit Opportunities Fund (ACOF). This fund is designed for investors seeking a tactical approach within the liquid alternative credit strategy landscape, blending daily liquidity with institutional-grade investment...

Continue Reading
Texas Court Advances Lawsuit for Houston Assistant Fire Chiefs

Updated Category News Views 162

Texas Court of Appeals Rules for Assistant Fire Chiefs The Fourteenth Court of Appeals has recently made a crucial ruling concerning the rights of thirteen Assistant Fire Chiefs in a legal dispute with both the City of Houston and the Houston Professional Fire Fighters' Association. This ruling allows these dedicated professionals, who play a vital role in ensuring the...

Continue Reading
Revolutionary Wireless Charging Device Enhances User Experience

Updated Category News Views 298

Innovative Wireless Charger Unveiled With the rapid evolution of technology, charging solutions are also advancing. A visionary inventor has introduced a groundbreaking device, designed to enhance the way we charge our phones. This device, known as the TACTIC, was conceived with a clear goal in mind: to make charging seamless, even while using the phone. Understanding the...

Continue Reading
Cunningham Bounds Elevates Joseph McGowin to Partner Role

Updated Category News Views 142

Cunningham Bounds Elevates Joseph McGowin to Partner Role Cunningham Bounds is thrilled to announce Joseph McGowin's promotion to Partner. This decision acknowledges his exceptional trial skills and unwavering commitment to representing individuals and families affected by negligence and wrongful conduct. Throughout his career, Joseph has fought tirelessly for his...

Continue Reading
Asetek's Q3 Performance Signals Future Growth Potential

Updated Category News Views 239

Asetek's Latest Financial Results Asetek has reported its financial results for the third quarter of 2025, noting a revenue of $9.8 million. This figure shows a decline compared to the $12.2 million reported in the same quarter of 2024. The company has faced fewer shipments of liquid cooling products, which has significantly affected revenue over these periods. Gross...

Continue Reading